Prescribing Information and the Label

The label is not marketing material but the negotiated output of the approval, and it draws the boundary between approved and off-label use. United States full prescribing information follows the Physician Labeling Rule format introduced in 2006: a Highlights page, a contents list, and numbered sections running from indications and dosing through warnings, adverse reactions, specific populations and clinical studies. The European equivalent is the Summary of Product Characteristics, published with an assessment report that shows the reasoning.

Particular sections carry weight for peptides. Clinical pharmacology gives the half-life, exposure and elimination route that set the dosing interval. Specific populations has followed the Pregnancy and Lactation Labeling Rule since 2015, which replaced the old letter categories with narrative risk summaries, and immunogenicity subsections give anti-drug antibody rates. Labels are revised throughout a product's life, so the current version belongs to the regulator's repository rather than a printed copy.

Used well, the label answers questions no secondary source can. It states the studied population, often much narrower than the disease name suggests, and its clinical studies section gives the effect size the approval rested on. It does not assert superiority over another drug unless that was studied and approved as a claim.

The frequent misreading treats the adverse reaction table as attributable risk, when those percentages include everything reported on treatment, which is why the placebo column sits beside them. The more consequential error transfers a label onto material it does not cover: a compounded or grey-market peptide has no approved labelling, and reproducing an approved product's information beside it implies a potency and stability profile nobody has assessed for that vial.